TY - JOUR
T1 - Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer
AU - Ledermann, Jonathan
AU - Harter, Philipp
AU - Gourley, Charlie
AU - Friedlander, Michael
AU - Vergote, Ignace
AU - Rustin, Gordon
AU - Scott, Clare
AU - Meier, Werner
AU - Shapira-Frommer, Ronnie
AU - Safra, Tamar
AU - Matei, Daniela
AU - Macpherson, Euan
AU - Watkins, Claire
AU - Carmichael, James
AU - Matulonis, Ursula
N1 - Funding Information:
This work was part funded by EPSRC, and the International Collaborative Energy Technology R&D Program of the Korean Institute of Energy Technology Evaluation and Planning (KETEP) with financial resource from the Ministry of Trade, Industry & Energy, Republic of Korea (no. 20148520011250). J. T.-W. W. acknowledges Swire Educational Trust for supporting his DPhil study at Oxford, and thanks Will Y.-K. Peng, and the members in the HJS and RJN group for helpful discussion. W. Z. thanks the Supergen super solar project for funding support. R. Z. thanks Prof. Bing Shen, Mr Haoran Ma and Xianguo Lang from the School of Earth and Space Sciences at Peking University for help in the ICP-OES analysis.
PY - 2012/4/12
Y1 - 2012/4/12
N2 - BACKGROUND: Olaparib (AZD2281) is an oral poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitor that has shown antitumor activity in patients with high-grade serous ovarian cancer with or without BRCA1 or BRCA2 germline mutations. METHODS: We conducted a randomized, double-blind, placebo-controlled, phase 2 study to evaluate maintenance treatment with olaparib in patients with platinum-sensitive, relapsed, high-grade serous ovarian cancer who had received two or more platinumbased regimens and had had a partial or complete response to their most recent platinum-based regimen. Patients were randomly assigned to receive olaparib, at a dose of 400 mg twice daily, or placebo. The primary end point was progression-free survival according to the Response Evaluation Criteria in Solid Tumors guidelines. RESULTS: Of 265 patients who underwent randomization, 136 were assigned to the olaparib group and 129 to the placebo group. Progression-free survival was significantly longer with olaparib than with placebo (median, 8.4 months vs. 4.8 months from randomization on completion of chemotherapy; hazard ratio for progression or death, 0.35; 95% confidence interval [CI], 0.25 to 0.49; P<0.001). Subgroup analyses of progression-free survival showed that, regardless of subgroup, patients in the olaparib group had a lower risk of progression. Adverse events more commonly reported in the olaparib group than in the placebo group (by more than 10% of patients) were nausea (68% vs. 35%), fatigue (49% vs. 38%), vomiting (32% vs. 14%), and anemia (17% vs. 5%); the majority of adverse events were grade 1 or 2. An interim analysis of overall survival (38% maturity, meaning that 38% of the patients had died) showed no significant difference between groups (hazard ratio with olaparib, 0.94; 95% CI, 0.63 to 1.39; P = 0.75). CONCLUSIONS: Olaparib as maintenance treatment significantly improved progression-free survival among patients with platinum-sensitive, relapsed, high-grade serous ovarian cancer. Interim analysis showed no overall survival benefit. The toxicity profile of olaparib in this population was consistent with that in previous studies. (Funded by Astra- Zeneca; ClinicalTrials.gov number, NCT00753545.).
AB - BACKGROUND: Olaparib (AZD2281) is an oral poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitor that has shown antitumor activity in patients with high-grade serous ovarian cancer with or without BRCA1 or BRCA2 germline mutations. METHODS: We conducted a randomized, double-blind, placebo-controlled, phase 2 study to evaluate maintenance treatment with olaparib in patients with platinum-sensitive, relapsed, high-grade serous ovarian cancer who had received two or more platinumbased regimens and had had a partial or complete response to their most recent platinum-based regimen. Patients were randomly assigned to receive olaparib, at a dose of 400 mg twice daily, or placebo. The primary end point was progression-free survival according to the Response Evaluation Criteria in Solid Tumors guidelines. RESULTS: Of 265 patients who underwent randomization, 136 were assigned to the olaparib group and 129 to the placebo group. Progression-free survival was significantly longer with olaparib than with placebo (median, 8.4 months vs. 4.8 months from randomization on completion of chemotherapy; hazard ratio for progression or death, 0.35; 95% confidence interval [CI], 0.25 to 0.49; P<0.001). Subgroup analyses of progression-free survival showed that, regardless of subgroup, patients in the olaparib group had a lower risk of progression. Adverse events more commonly reported in the olaparib group than in the placebo group (by more than 10% of patients) were nausea (68% vs. 35%), fatigue (49% vs. 38%), vomiting (32% vs. 14%), and anemia (17% vs. 5%); the majority of adverse events were grade 1 or 2. An interim analysis of overall survival (38% maturity, meaning that 38% of the patients had died) showed no significant difference between groups (hazard ratio with olaparib, 0.94; 95% CI, 0.63 to 1.39; P = 0.75). CONCLUSIONS: Olaparib as maintenance treatment significantly improved progression-free survival among patients with platinum-sensitive, relapsed, high-grade serous ovarian cancer. Interim analysis showed no overall survival benefit. The toxicity profile of olaparib in this population was consistent with that in previous studies. (Funded by Astra- Zeneca; ClinicalTrials.gov number, NCT00753545.).
UR - http://www.scopus.com/inward/record.url?scp=84859523588&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84859523588&partnerID=8YFLogxK
U2 - 10.1056/NEJMoa1105535
DO - 10.1056/NEJMoa1105535
M3 - Article
C2 - 22452356
AN - SCOPUS:84859523588
SN - 0028-4793
VL - 366
SP - 1382
EP - 1392
JO - New England Journal of Medicine
JF - New England Journal of Medicine
IS - 15
ER -
